NCT04164979

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.

Detailed description

Treatment on study will be administered in 21 day cycles.

Conditions

• Gastric Adenocarcinoma
• GastroEsophageal Cancer

Interventions

Type	Name	Description
DRUG	Cabozantinib	Given PO
DRUG	Pembrolizumab	Given IV

Timeline

• Start date: 2020-02-04
• Primary completion: 2023-11-25
• Completion: 2026-05-30
• First posted: 2019-11-15
• Last updated: 2025-08-11
• Results posted: 2025-08-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study